Stifel Downgrades Aclaris Therapeutis (ACRS) to Hold, 'Zunsemetinib Thesis Broken'
Tweet Send to a Friend
(Updated - November 13, 2023 10:39 AM EST)
Stifel analyst Alex Thompson downgraded Aclaris Therapeutis (NASDAQ: ACRS) from Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Alex Thompson downgraded Aclaris Therapeutis (NASDAQ: ACRS) from Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
